Business Context and Reporting Period
This Form 8-K is a current report filed by Voyager Therapeutics, Inc. on February 12, 2026, covering events occurring on February 9, 2026. The company is a Delaware corporation with its principal executive offices in Lexington, Massachusetts, and its common stock trades on the Nasdaq Global Select Market under the symbol VYGR.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Departure of Chief Medical Officer: Toby Ferguson, M.D., Ph.D., resigned as Chief Medical Officer and from all other positions with the Company and its subsidiaries. The resignation is effective February 20, 2026.
- Reason for Departure: Dr. Ferguson is leaving to pursue a new opportunity. The filing explicitly states the resignation is not the result of any disagreement with the Company.
- Interim Leadership: Alfred W. Sandrock, Jr., M.D., Ph.D., the current President and Chief Executive Officer, has agreed to assume key responsibilities, including strategic guidance for clinical development programs, on an interim basis following Dr. Ferguson's departure.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of material risks and contingencies beyond the operational transition of the Chief Medical Officer role. No unusual items were reported.
Investor Verification Checklist
- Confirm the effective date of Dr. Ferguson's resignation (February 20, 2026).
- Verify the scope of interim responsibilities assumed by CEO Alfred W. Sandrock, Jr., specifically regarding clinical development programs.
- Monitor future filings for the appointment of a permanent Chief Medical Officer.
- Review subsequent quarterly reports (10-Q) or annual reports (10-K) for any financial impact related to this leadership transition.